These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 36142566)
1. Machine Learning-Based Virtual Screening for the Identification of Cdk5 Inhibitors. Di Stefano M; Galati S; Ortore G; Caligiuri I; Rizzolio F; Ceni C; Bertini S; Bononi G; Granchi C; Macchia M; Poli G; Tuccinardi T Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142566 [TBL] [Abstract][Full Text] [Related]
2. Identification of New GSK3β Inhibitors through a Consensus Machine Learning-Based Virtual Screening. Galati S; Di Stefano M; Bertini S; Granchi C; Giordano A; Gado F; Macchia M; Tuccinardi T; Poli G Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139062 [TBL] [Abstract][Full Text] [Related]
3. Discovery of Monoacylglycerol Lipase (MAGL) Inhibitors Based on a Pharmacophore-Guided Virtual Screening Study. Jha V; Biagi M; Spinelli V; Di Stefano M; Macchia M; Minutolo F; Granchi C; Poli G; Tuccinardi T Molecules; 2020 Dec; 26(1):. PubMed ID: 33375358 [TBL] [Abstract][Full Text] [Related]
4. Virtual screening, pharmacokinetics, molecular dynamics and binding free energy analysis for small natural molecules against cyclin-dependent kinase 5 for Alzheimer's disease. Shukla R; Singh TR J Biomol Struct Dyn; 2020 Jan; 38(1):248-262. PubMed ID: 30688165 [TBL] [Abstract][Full Text] [Related]
6. Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening. Chatterjee A; Cutler SJ; Doerksen RJ; Khan IA; Williamson JS Bioorg Med Chem; 2014 Nov; 22(22):6409-21. PubMed ID: 25438765 [TBL] [Abstract][Full Text] [Related]
7. Desmodin and isopongachromene as potential inhibitors of cyclin-dependent kinase 5: phytoconstituents targeting anticancer and neurological therapy. Atiya A; Batra S; Mohammad T; Alorfi NM; Abdulmonem WA; Alhumaydhi FA; Ashraf GM; Baeesa SS; Elasbali AM; Shahwan M J Biomol Struct Dyn; 2023; 41(16):8042-8052. PubMed ID: 36184739 [TBL] [Abstract][Full Text] [Related]
8. Cdk5: multitasking between physiological and pathological conditions. Lopes JP; Agostinho P Prog Neurobiol; 2011 Jun; 94(1):49-63. PubMed ID: 21473899 [TBL] [Abstract][Full Text] [Related]
9. Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling. Demange L; Abdellah FN; Lozach O; Ferandin Y; Gresh N; Meijer L; Galons H Bioorg Med Chem Lett; 2013 Jan; 23(1):125-31. PubMed ID: 23218601 [TBL] [Abstract][Full Text] [Related]
10. Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease. Allnutt AB; Waters AK; Kesari S; Yenugonda VM ACS Chem Neurosci; 2020 May; 11(9):1218-1230. PubMed ID: 32286796 [TBL] [Abstract][Full Text] [Related]
11. Three decades of Cdk5. Pao PC; Tsai LH J Biomed Sci; 2021 Nov; 28(1):79. PubMed ID: 34814918 [TBL] [Abstract][Full Text] [Related]
12. [Roles of cyclin-dependent kinase 5 in central nervous system development and neurodegenerative diseases]. Chen J; Wang ZF Sheng Li Xue Bao; 2010 Aug; 62(4):295-308. PubMed ID: 20717630 [TBL] [Abstract][Full Text] [Related]
13. De Novo Rational Design of Peptide-Based Protein-Protein Inhibitors (Pep-PPIs) Approach by Mapping the Interaction Motifs of the PP Interface and Physicochemical Filtration: A Case on p25-Cdk5-Mediated Neurodegenerative Diseases. Oduro-Kwateng E; Ali M; Kehinde IO; Zhang Z; Soliman MES J Cell Biochem; 2024 Sep; 125(9):e30633. PubMed ID: 39148280 [TBL] [Abstract][Full Text] [Related]
14. Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders. Zeb A; Son M; Yoon S; Kim JH; Park SJ; Lee KW Comput Struct Biotechnol J; 2019; 17():579-590. PubMed ID: 31073393 [TBL] [Abstract][Full Text] [Related]
15. Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study. Shahroz MM; Sharma HK; Altamimi ASA; Alamri MA; Ali A; Ali A; Alqahtani S; Altharawi A; Alabbas AB; Alossaimi MA; Riadi Y; Firoz A; Afzal O Molecules; 2022 Feb; 27(4):. PubMed ID: 35208955 [TBL] [Abstract][Full Text] [Related]
16. Identifying natural compounds as multi-target-directed ligands against Alzheimer's disease: an in silico approach. Ambure P; Bhat J; Puzyn T; Roy K J Biomol Struct Dyn; 2019 Mar; 37(5):1282-1306. PubMed ID: 29578387 [TBL] [Abstract][Full Text] [Related]
17. Structural basis of valmerins as dual inhibitors of GSK3β/CDK5. Li X; Wang X; Tian Z; Zhao H; Liang D; Li W; Qiu Y; Lu S J Mol Model; 2014 Sep; 20(9):2407. PubMed ID: 25142337 [TBL] [Abstract][Full Text] [Related]
18. An in silico approach for the discovery of CDK5/p25 interaction inhibitors. Zhang B; Corbel C; Guéritte F; Couturier C; Bach S; Tan VB Biotechnol J; 2011 Jul; 6(7):871-81. PubMed ID: 21681969 [TBL] [Abstract][Full Text] [Related]
19. Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery. Fang J; Yang R; Gao L; Yang S; Pang X; Li C; He Y; Liu AL; Du GH Mol Divers; 2015 Feb; 19(1):149-62. PubMed ID: 25511641 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of cyclin-dependent kinase 5 affects early neuroinflammatory signalling in murine model of amyloid beta toxicity. Wilkaniec A; Gąssowska-Dobrowolska M; Strawski M; Adamczyk A; Czapski GA J Neuroinflammation; 2018 Jan; 15(1):1. PubMed ID: 29301548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]